Juva Life Inc
CNSX:JUVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (1.2), the stock would be worth CA$0.02 (0% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.2 | CA$0.02 |
0%
|
| 3-Year Average | 1.2 | CA$0.02 |
+0%
|
| 5-Year Average | 1.4 | CA$0.02 |
+16%
|
| Industry Average | 1.5 | CA$0.02 |
+23%
|
| Country Average | 2.9 | CA$0.05 |
+147%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
J
|
Juva Life Inc
CNSX:JUVA
|
2.5m CAD | 1.2 | -0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 13.3 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.2 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 5.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 4.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 4.1 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 3.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 3.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 2.9 |
| 70th Percentile | 5.7 |
| Max | 15 639 353.3 |
Other Multiples
Juva Life Inc
Glance View
Juva Life, Inc. engages in the cultivation, manufacturing, research and development, distribution and retail of medical and recreational cannabis. The company is headquartered in Vancouver, British Columbia and currently employs 24 full-time employees. The company went IPO on 2020-10-21. The firm operates in the medical and recreational cannabis sectors. The firm acquires, owns, and operates cannabis business in California. The firm is focused on the research, development, and commercialization of Cannabis products. Its initial pre-clinical discovery is Juva-019, is a non-cannabinoid purified small molecule isolated from Cannabis with broad spectrum anti-inflammatory properties. Juva-019 is a potent modulator of TNF-alpha, IL-1 beta, and several other clinically relevant cytokines. The firm has developed a chemical library of natural and semi-synthetic non-cannabinoids and is evaluating their therapeutic benefit alone and in combination across panels of industry-standard phenotypic and target-based anti-inflammatory assays.
